Bis(3,5-dibromophenyl)methane | 160976-67-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Bis(3,5-dibromophenyl)methane
• 英文别名: bis(3,5-dibromodiphenyl)methane；1,3-dibromo-5-[(3,5-dibromophenyl)methyl]benzene
• CAS: 160976-67-0
• 化学式: C₁₃H₈Br₄
• 分子量: 483.823
• InChiKey: GOVVHILETNGOIN-UHFFFAOYSA-N

物化性质

• 沸点：
  463.0±40.0 °C(Predicted)
• 密度：
  2.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  Bis(3,5-dibromophenyl)methane 在 磷化氢 、 碘 、 叔丁基锂 作用下， 以 四氢呋喃 、 溶剂黄146 、 正戊烷 为溶剂， 反应 71.0h， 生成 5,11,17,23-Tetraformyl-calix[4]arene
  参考文献：
  名称：

  Synthesis of [1.1.1.1]Metacyclophane Macrocycle

  摘要：

  Additions of organodilithium reagents to dialdehydes allow for construction of [1.1.1.1]metacyclophane macrocycle in similar to 40% yield in the ring forming step, without resort to standard high dilution techniques. The present methodology is complementary to the conventional condensations leading to phenol- and resorcinol-based cyclotetramers.

  DOI：

  10.1021/jo00104a027
• 作为产物：
  描述：

  4,4'-二氨基二苯甲烷 在 硫酸 、 溴 、 sodium nitrite 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 3.5h， 生成 Bis(3,5-dibromophenyl)methane
  参考文献：
  名称：

  分子线和器件的合成和初步测试。

  摘要：

  本文介绍了几种共轭低聚（亚苯基乙炔基）合成路线。这些低聚物中的一些不含官能团，而其他则具有供体基团，受体基团，卟啉内部以及用于各种潜在传输和数字设备应用的其他杂环内部。提出了具有各种端基的低聚（亚苯基亚乙炔基）的合成方法，该低端基用于连接许多金属探针和表面。一些功能化分子系统表现出线性，线状，电流对电压（I（V））响应，而另一些则表现出负差分电阻（NDR）和分子随机存取记忆效应的非线性I（V）曲线。最后，描述了可以在金属电极上形成自组装单分子层的功能化低聚物的合成，从而降低了肖特基势垒。肖特基势垒研究的信息可以为分子电子学中的分子鳄鱼夹优化提供有用的见解。

  DOI：

  10.1002/1521-3765(20011203)7:23<5118::aid-chem5118>3.0.co;2-1

文献信息

• Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040054173A1

  公开（公告）日：2004-03-18

  Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1 A′ is pyrrole; R 1′ is phenyl or naphthyl; R 2′ is pyridyl or pyrimidinyl; R 3′ is (IIa)′, (IIb)′ or (IIc)′: 2 m′ is 1; E′ is nitrogen; D′ is >C(R 5′ )—, R 5′ is hydrogen, Substituent &agr;′ or Substituent &bgr;′; B′ is nitrogen-containing 5-membered heterocyclic; R 4′ is 1 to 3 substituents from Substituent &agr;′, Substituent &bgr;′ and Substituent &ggr;′; R 1′ and R 3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R 2′ ; Substituent &agr;′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NR a′ R b′ ; R a′ and R b′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or R a′ and R b′ with the nitrogen atom form a heterocyclyl; Substituent &bgr;′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent &ggr;′ is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.

  具有对抗公式(I)′炎症细胞因子生成活性的化合物： 1 A′是吡咯；R 1′ 是苯基或萘基；R 2′ 是吡啶基或嘧啶基；R 3′ 是(IIa)′，(IIb)′或(IIc)′： 2 m′是1；E′是氮；D′是>C(R 5′ )—, R 5′ 是氢，取代基α′或取代基β′；B′是含氮的5-成员杂环；R 4′ 是来自取代基α′，取代基β′和取代基γ′的1至3个取代基；R 1′ 和R 3′ 分别与吡咯环上与R 2′ 相连的吡咯原子的两个相邻原子成键；取代基α′是羟基，硝基，氰基，卤素，烷氧基，卤代烷氧基，烷基亚砜，卤代烷基亚砜或—NR a′ R b′ ；R a′ 和R b′ 是氢，烷基，烯基，炔基，芳烷基或烷基亚磺酰基，或者R a′ 和R b′ 与氮原子形成杂环；取代基β′是烷基，烯基，炔基，芳烷基或环烷基；取代基γ′是氧代，羟基亚胺，烷氧基亚胺，亚烷基，亚烷基二氧，烷基亚磺酰基，烷基亚磺酰基，芳基，芳氧基，亚烷基或芳亚烷基。
• Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses
  申请人：Sankyo Company Limited

  公开号：EP1243589A1

  公开（公告）日：2002-09-25

  Compounds of formula (I): [wherein: A is a pyrrole ring; R1 is an optionally substituted phenyl or naphthyl group; R2 is an optionally substituted pyridyl or pyrimidinyl group; R3 represents a group of the formula -X-R4, wherein X is a single bond or an alkenylene group, and R4 is an optionally substituted nitrogen-containing heterocyclyl group; selected from the group consisting of 8-azabicyclo[3.2.1]octenyl, 9-azabicyclo[3.3.1]nonenyl and quinuclidinenyl groups, PROVIDED THAT said substituents R1 and R3 are bonded to the two atoms of said pyrrole ring which are adjacent to the atom of the pyrrole ring to which said substituent R2 is bonded] have excellent inhibitory activity against the production of inflammatory cytokines.

  化合物的结构式（I）：[其中：A为吡咯环；R1为可选取代的苯或萘基团；R2为可选取代的吡啶或嘧啶基团；R3代表具有下述结构的基团-X-R4，其中X为单键或烯基链，R4为可选取代的含氮杂环基团；所选取自8-氮杂双环[3.2.1]辛烯基、9-氮杂双环[3.3.1]壬烯基和喹啉环基团，前提是所述取代基R1和R3连接到所述吡咯环的两个相邻原子，这两个原子与所述取代基R2连接的吡咯环原子相邻]具有出色的抑制炎症细胞因子产生活性。
• Introduction of cavities up to 4 nm into a hierarchically-assembled metal–organic framework using an angular, tetratopic ligand
  作者：Wenjuan Zhuang、Shengqian Ma、Xi-Sen Wang、Daqiang Yuan、Jian-Rong Li、Dan Zhao、Hong-Cai Zhou

  DOI：10.1039/c0cc00779j

  日期：——

  Cavities up to 4 nm have been introduced into a hierarchically-assembled metal–organic framework by adopting an angular, semi-flexible tetratopic ligand. The resulting MOF possesses permanent porosity and exhibits stepwise sorption isotherms for O2 and N2 gases.

  通过采用有角的半柔性四位配体，在分层组装的金属有机框架中引入了高达 4 nm 的空腔。所得 MOF 具有永久孔隙率，并对 O2 和 N2 气体表现出逐步吸附等温线。
• Three-terminal field-controlled molecular devices
  申请人：Tour M. James

  公开号：US20050101063A1

  公开（公告）日：2005-05-12

  The present invention comprises three-terminal molecules devices that provide an electronic switching or modulation function in response to an electric field that is optimally directed normally to the length of the molecule or molecules which form the conductive path between tow electrodes. This invention also provides synthetic routes that can be implemented to realize these devices using top-down and bottom-up fabrication approaches that are compatible with ultra-high density integration onto substrates.

  本发明包括三端分子器件，其在电场作用下提供电子开关或调制功能，该电场最佳地垂直于形成两个电极之间的导电通路的分子或分子的长度。本发明还提供了可以实现这些器件的合成路线，使用自上而下和自下而上的制造方法，这些方法与超高密度集成到基板上是兼容的。
• Compounds substituted with bicyclic amino groups
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040147525A1

  公开（公告）日：2004-07-29

  Compounds of the formula (I) below, or pharmacologically acceptable salts, esters or other derivatives thereof: 1 wherein A is furan, thiophene, pyrazole, imidazole, isoxazole or isothiazole; R 1 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; R 2 is a substituted or unsubstituted heteroaryl; and R 3 is a bicyclic amino group; provided that the substituents R 1 and R 2 are bonded to the two atoms of the cyclic group A which are adjacent to the atom of the cyclic group A to which the substituent R 2 is bonded. The compounds inhibit the production of inflammatory cytokines.

  以下式子（I）的化合物，或其药理学上可接受的盐，酯或其他衍生物：1其中A是呋喃，噻吩，吡唑，咪唑，异唑或异噻唑; R1是取代或未取代的芳基或取代或未取代的杂环芳基; R2是取代或未取代的杂环芳基; R3是双环氨基; 前提是取代基R1和R2与环族A的两个原子相连，这些原子邻接于取代基R2所连接的环族A原子。这些化合物抑制炎性细胞因子的产生。